OXFORD, Miss., Oct. 2, 2006 (PRIMEZONE) -- Modern Technology Corp (OTCBB:MODC), a diversified technology development and acquisition company, today announced its subsidiary, Insight Medical Group, has signed a Letter of Intent to acquire 100% of the assets and intellectual and technology rights to the Boveran iCyte cancer detection system. Insight Medical Group will be the operational arm bringing this technology to a multi-billion dollar international market.
The Boveran's unique cancer detection system, iCyte, is based on chromosomal imbalance, the only cell trait common to all forms of cancer and never found in healthy cells. From a biopsy or tissue sample, this technology rapidly and accurately identifies cancer at any stage in its development. At the same time it has the added benefit of identifying cancer-free biopsies. iCyte technology, once applied to a cell sample, can return a reliable test result within minutes.
What makes this system exclusive is its ability to sample any form of biopsy or tissue suspected of cancer. It eliminates previously unreliable, subjective and error-prone conventional diagnoses, delivering within minutes an automated and objective report with the highest accuracy rate of any diagnostic system in the world.
iCyte's detection method is especially important for the reliable and early discovery of breast, cervical, and prostate cancers. The dependable elimination of false-positives, false-negatives and indeterminates from any tissue source is the hallmark of the iCyte system. The high rate of error in the current testing protocols has been the bane of the cancer diagnostic industry throughout its entire history. For the first time, the trustworthy results of iCyte diagnostics eliminate these challenges.
The iCyte system was developed with the direction of Dr. David Rasnick, based on research with Dr. Peter Duesberg. Their research has yielded the only comprehensive, coherent and productive theory of cancer that explains its genesis, evolution and characteristics. From this foundation of solid science, the iCyte cancer detection system was created.
The system has undergone pre-clinical testing and has proven itself to function as expected and deliver accurate and rapid results. The iCyte system's cellular scanning technology can deliver information that can be used to immediately determine the presence or absence of cancer in any biopsy sample without the up to 50% error rate common of current procedures. The iCyte system removes false negatives and the equally important, but often overlooked, problem of false-positives that millions of patients experience annually.
The market space for this diagnostic tool is massive and competition-free. No other system in the world can analyze biopsies from any tissue source for the cell characteristic targeted by iCyte. The company believes the iCyte system will quickly become the de facto gold standard for determining the presence or absence of cancer.
iCyte can be applied to all forms of cancer. No other cancer diagnostic system in the world can be applied to more than a few targeted types of cancer and even then not as reliably because they do not use the technique found in iCyte. iCyte delivers the highest accuracy rate of any technique in existence. iCyte is unique in the world by its approach and measurement of the common denominator that all cancers share.
Anthony Welch, Chairman said: "This acquisition is the single most important moment for the company and the finest moment in my professional career. The technology and the people involved behind it are all world-class. We are entering a multi-billion dollar market space with a completely unique and proven technology that has no rival or peer. We will release frequent updates on Insight Medical Group's operational progress, revenue expectations, and international expansion for this system. The company will rapidly appear in the international spotlight for a variety of reasons. We will have the world's expectations set high for us and we intend to fulfill that obligation with absolute professionalism, performance, and solid science. All of our recent corporate changes have been made to better align the company to supporting this new effort and the outstanding individuals behind it."
About Dr. David Rasnick and Dr. Peter Duesberg
Dr. David Rasnick, with 25 years experience, holding 9 patents, worked in the pharmaceutical/biotech industry on cancer, emphysema, arthritis, and parasitic diseases. A critical turning point was in 1996, when Dr. Rasnick joined Professor Peter Duesberg at University of California at Berkeley. This union began a new and exciting understanding of cancer, creating a paradigm shift and resolving the inherent problems faced by the current school of thought. In less than 3 years, Rasnick and Duesberg established Boveran, Inc. With Rasnick's leadership Boveran grew to provide a unique and completely accurate method of detecting all forms of cancer and pre-cancerous conditions.
Peter H. Duesberg, Ph.D. is a professor of Molecular and Cell Biology at the University of California, Berkeley. He isolated the first cancer gene through his work on retroviruses in 1970, and mapped the genetic structure of these viruses. This, and his subsequent work in the same field, resulted in his election to the National Academy of Sciences in 1986. He was also the recipient of a seven-year Outstanding Investigator Grant from the National Institute of Health.
In 1987 he argued HIV is not the cause of AIDS and has published a number of scientific papers on this topic including the now famous book "Inventing the AIDS Virus."
Duesberg and his work in cancer research were recently mentioned in an article found in Newsweek. Found here: http://www.msnbc.msn.com/id/14757547/site/newsweek/
In 2003, Scientific American explained Rasnick and Duesberg's new understanding of cancer in a major article, placing their discoveries in the context of 100 years of cancer research. A recent internet search revealed nearly a thousand citations of Rasnick and Duesberg's work.
About Insight Medical Group
Insight Medical Group is a specialized biosciences development company whose mission is to bring world changing medical technology and research to market in the areas of cancer and AIDS.
About Modern Technology Corp
Modern Technology Corp, a diversified technology development and acquisition company, builds revenues through continuous growth, strategic acquisitions, and commercialization of nascent technology. MODC improves operating efficiencies through the elimination of cost redundancies and realized synergy between subsidiaries. Web Address: http://www.moderntechnologycorp.com
Safe-Harbor Statement
This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to those detailed from time to time in the Company's filings with the Securities and Exchange Commission.